ABPI statement on the death of Her Majesty Queen Elizabeth II

08 September 2022 Posted in News by Press Office

ABPI statement on the death of Her Majesty Queen Elizabeth II: 

On behalf of the ABPI and the pharmaceutical industry in the UK, I would like to extend our condolences to the Royal Family. Richard Torbett, Chief Executive, ABPI

ABPI Chief Executive Richard Torbett said: 

“On behalf of the ABPI and the pharmaceutical industry in the UK, I would like to extend our condolences to the Royal Family.

“The Queen led a life of duty and service to the people of the UK & Commonwealth and was an inspirational figurehead for the UK around the world.  

“She leaves behind an unmatched legacy of dignified leadership and our industry joins with the rest of the nation in mourning at this sad time.”

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.

Media enquiries

+44 (0) 20 7747 7147​​